Home » Newsletters » BioWorld Science

BioWorld Science

Sep. 6, 2012

View Archived Issues

Novel antithrombotic agents presented by Bristol-Myers Squibb

New tamsulosin prodrugs prepared by Synthon

Affectis Pharmaceuticals presents novel P2X7 receptor antagonists

Novel monoclonal antibodies patented by IRM and Novartis

Mepolizumab reduces exacerbation rates in asthma patients

Third patient successfully treated with Pluristem's PLX cells

Phase I/II ublituximab trial begins in B-cell non-Hodgkin's lymphoma

Researchers at Zyngenia disclose novel fusion proteins

Light study of Contrave experiences accelerated enrollment

Oncothyreon expands phase II trial of PX-866

Novel S1P4 receptor antagonists synthesized by Biogen Idec

ImmunoCellular Therapeutics completes enrollment in ICT-107 trial

BT-2111 shows promise in animal models of breast cancer

Adynxx's AYX-1 set to move to phase II

Targacept to develop TC-5214 in overactive bladder

Phase II results demonstrate efficacy of QMF-149 in patients with persistent asthma

ALV-003 receives FDA fast track designation for celiac disease

New lysophospholipid S1P1 receptor agonists presented at ACS meeting

Rienso receives Swiss marketing authorization

NPS Pharmaceuticals updates plans for Natpara BLA

Baxter begins phase I monoclonal antibody trial in patients with solid tumors

Acadia Pharmaceuticals completes enrollment in phase III pimavanserin trial

Study evaluates dose-response of umeclidinium in COPD

Meda to buy Jazz Pharmaceuticals' women's health business

FDA extends PDUFA date for Ravicti NDA

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for June 12, 2026.
News in brief
BioWorld Asia
BioWorld Asia briefs for June 9, 2026
Pre-disease plasma signature may help redefine lung cancer risk
BioWorld
Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...
Europe’s Alzecure, Orionis in $1B+ deals with Lilly, Novartis
BioWorld
Two companies with European ties signed billion-dollar deals with large pharma firms in the last two days to discover and develop molecular glue drugs, as well as...
Ethyreal launches to treat the underlying cause of Graves’, TED
BioWorld
Ethyreal Bio Inc. has come out of stealth mode in order to disclose preclinical data for ETHY-001, its monoclonal antibody targeting thyroid stimulating hormone...